As per terms of the deal, Boston Pharmaceuticals purchased global rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas. The anti-infective drug candidates
The post Boston Pharmaceuticals buys Novartis’ three anti-infective drug candidates appeared first on Pharma Business review.